CA2879252C — Combination therapies for melanoma comprising administering cobimetinib and vemurafinib
Assigned to F Hoffmann La Roche AG · Expires 2017-10-10 · 9y expired
What this patent protects
The present invention relates generally to the fields of molecular biology and growth factor regulation. More specifically, the invention relates to therapies for the treatment of pathological conditions, such as cancer. Even more specifically, the invention relates to compositio…
USPTO Abstract
The present invention relates generally to the fields of molecular biology and growth factor regulation. More specifically, the invention relates to therapies for the treatment of pathological conditions, such as cancer. Even more specifically, the invention relates to compositions comprising cobimetinib and vemurafenib and their use in the treatment of BRAF-V600 mutation-positive unresectable or metastatic melanoma.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.